Namsa underlines interest in European market with latest deal

Medtech CRO Namsa says acquisition of German contractor CRI – the Clinical Research Institute – is about expanding its reach in Europe.

Toledo, Ohio-based Namsa bought CRI in mid-July, citing the firm’s experience and use of data solutions as primary motivations for the deal.

The deal was also about adding scale according to Christophe Berthoux, Namsa CEO. “The addition of this organization to the Namsa family is a significant move for us in Germany that enhances and expands our CRO offerings throughout Europe and across all markets.”

This view is shared by CRI CEO Thomas Fetsch, who said “both companies share identical values and are wholeheartedly committed to delivering unparalleled service and resources to the medical device and diagnostic sectors.

“With a team of seasoned experts well versed in the fields of medicine and science, CRI is thrilled to join forces with NAMSA to bolster their global presence, particularly in Europe,” he added.
Elisabeth Freund, CRI Founder, went further, predicting that combined the CRO would corner the market in certain fast-expanding therapeutic markets.

“Together, the collective proficiency of both organizations will establish them as the foremost MedTech CRO for Cardiovascular research services across the globe,” she said, adding “I am confident in the abilities of our teams to leverage expertise and continue to deliver superior results to our global clients.”

The acquisition in the eighth Namsa has made since it was bought by healthcare-focused global private equity company Archimed in 2020. Previous takeovers include the acquisition of Philadelphia’s Clinlogix, Syntactx and APS.

The CRI deal is further indication of Namsa’s interest in winning business from customers targeting the European medicial device market. For example, in March, it bought SUAZIO, an EU-based strategic consultancy providing global market research services to medical device and IVD developers.

DepositPhotos/IgorVetushko